"Anemia, Sideroblastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.
| Descriptor ID |
D000756
|
| MeSH Number(s) |
C15.378.071.419 C15.378.190.625.070
|
| Concept/Terms |
Anemia, Sideroblastic- Anemia, Sideroblastic
- Anemias, Sideroblastic
- Sideroblastic Anemia
- Sideroblastic Anemias
|
Below are MeSH descriptors whose meaning is more general than "Anemia, Sideroblastic".
Below are MeSH descriptors whose meaning is more specific than "Anemia, Sideroblastic".
This graph shows the total number of publications written about "Anemia, Sideroblastic" by people in this website by year, and whether "Anemia, Sideroblastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anemia, Sideroblastic" by people in Profiles.
-
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). J Clin Immunol. 2023 05; 43(4):780-793.
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
-
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 04; 36(4):1189-1192.
-
A phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay. Am J Med Genet A. 2022 01; 188(1):259-268.
-
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 01; 63(1):199-204.
-
SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Hum Mutat. 2021 11; 42(11):1367-1383.
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
-
MDS/MPN-RS-T justified inclusion as a unique disease entity? Best Pract Res Clin Haematol. 2020 06; 33(2):101147.
-
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 01 09; 382(2):140-151.
-
Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res. 2019 11; 86:106227.